331 related articles for article (PubMed ID: 16798086)
1. Stop-codon read-through for patients affected by a lysosomal storage disorder.
Brooks DA; Muller VJ; Hopwood JJ
Trends Mol Med; 2006 Aug; 12(8):367-73. PubMed ID: 16798086
[TBL] [Abstract][Full Text] [Related]
2. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.
Hein LK; Bawden M; Muller VJ; Sillence D; Hopwood JJ; Brooks DA
J Mol Biol; 2004 Apr; 338(3):453-62. PubMed ID: 15081804
[TBL] [Abstract][Full Text] [Related]
3. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
[TBL] [Abstract][Full Text] [Related]
4. Therapy for lysosomal storage disorders.
Beck M
IUBMB Life; 2010 Jan; 62(1):33-40. PubMed ID: 20014233
[TBL] [Abstract][Full Text] [Related]
5. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.
Malik V; Rodino-Klapac LR; Viollet L; Wall C; King W; Al-Dahhak R; Lewis S; Shilling CJ; Kota J; Serrano-Munuera C; Hayes J; Mahan JD; Campbell KJ; Banwell B; Dasouki M; Watts V; Sivakumar K; Bien-Willner R; Flanigan KM; Sahenk Z; Barohn RJ; Walker CM; Mendell JR
Ann Neurol; 2010 Jun; 67(6):771-80. PubMed ID: 20517938
[TBL] [Abstract][Full Text] [Related]
6. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
Keeling KM; Bedwell DM
J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912
[TBL] [Abstract][Full Text] [Related]
7. Treatment of a methylmalonyl-CoA mutase stopcodon mutation.
Buck NE; Wood LR; Hamilton NJ; Bennett MJ; Peters HL
Biochem Biophys Res Commun; 2012 Nov; 427(4):753-7. PubMed ID: 23041189
[TBL] [Abstract][Full Text] [Related]
8. [Current therapeutic strategies in lysosomal disorders].
Kaminsky P; Lidove O
Presse Med; 2014 Nov; 43(11):1174-84. PubMed ID: 24863660
[TBL] [Abstract][Full Text] [Related]
9. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment.
Bidou L; Hatin I; Perez N; Allamand V; Panthier JJ; Rousset JP
Gene Ther; 2004 Apr; 11(7):619-27. PubMed ID: 14973546
[TBL] [Abstract][Full Text] [Related]
10. Effects of gentamicin inducing readthrough premature stop Codons: A study of alpha-L-iduronidase nonsense variants in COS-7 Cells.
Ngiwsara L; Sawangareetrakul P; Wattanasirichaigoon D; Tim-Aroon T; Dejkhamron P; Champattanachai V; Ketudat-Cairns JR; Svasti J
Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):147-154. PubMed ID: 36332477
[TBL] [Abstract][Full Text] [Related]
11. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.
Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM
Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948
[TBL] [Abstract][Full Text] [Related]
12. Current strategies in the management of lysosomal storage diseases.
Heese BA
Semin Pediatr Neurol; 2008 Sep; 15(3):119-26. PubMed ID: 18708002
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases.
Gómez-Grau M; Garrido E; Cozar M; Rodriguez-Sureda V; Domínguez C; Arenas C; Gatti RA; Cormand B; Grinberg D; Vilageliu L
PLoS One; 2015; 10(8):e0135873. PubMed ID: 26287674
[TBL] [Abstract][Full Text] [Related]
14. [Lysosomes and lysosomal storage diseases].
Germain DP
J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for the lysosomal storage disorders.
Cabrera-Salazar MA; Novelli E; Barranger JA
Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
[TBL] [Abstract][Full Text] [Related]
16. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.
Hemsley KM; Luck AJ; Crawley AC; Hassiotis S; Beard H; King B; Rozek T; Rozaklis T; Fuller M; Hopwood JJ
Eur J Neurosci; 2009 Mar; 29(6):1197-214. PubMed ID: 19302155
[TBL] [Abstract][Full Text] [Related]
17. Treatments for lysosomal storage disorders.
Lachmann R
Biochem Soc Trans; 2010 Dec; 38(6):1465-8. PubMed ID: 21118108
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging therapies for the lysosomal storage disorders.
Pastores GM; Barnett NL
Expert Opin Emerg Drugs; 2005 Nov; 10(4):891-902. PubMed ID: 16262569
[TBL] [Abstract][Full Text] [Related]
19. Detection of heterozygous nonsense mutations in genes of interest using an Escherichia coli-based stop codon assay.
Moon YJ; Kang Y; Choi JH; Lee KH
Biotechnol Appl Biochem; 2007 Feb; 46(Pt 2):137-43. PubMed ID: 16995837
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders.
Desnick RJ; Schuchman EH
Nat Rev Genet; 2002 Dec; 3(12):954-66. PubMed ID: 12459725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
